MiNK Therapeutics, Inc. reports developments in clinical-stage biopharmaceutical programs built around allogeneic invariant natural killer T cell therapies. Its proprietary iNKT platform is designed to bridge innate and adaptive immunity, with agenT-797 as an off-the-shelf allogeneic iNKT cell therapy evaluated across cancer, immune-mediated disease and pulmonary immune-failure settings.
Company news commonly covers clinical and translational data, scientific-conference presentations, financial results, platform expansion, strategic collaborations and non-dilutive funding tied to iNKT cell therapy programs. Recurring program areas include solid tumors, gastroesophageal cancer, graft-versus-host disease, severe pulmonary inflammation, ARDS or hypoxemic pneumonia, and PRAME-targeted TCR-engineered iNKT approaches for pediatric cancers.
MiNK Therapeutics (NASDAQ: INKT) will hold its Annual Shareholders Meeting virtually on June 12, 2024, starting at 9:30 a.m. ET. Shareholders can register from 9:15 a.m. ET by visiting www.virtualshareholdermeeting.com/INKT2024 and using their 16-digit control number from proxy materials. Guests can access the meeting in listen-only mode without a control number. A live webcast and replay will be available on the company's website.
MiNK Therapeutics has unveiled clinical data on their allogeneic invariant natural killer T (iNKT) cell therapy, agenT-797, in a severe ARDS case at the ATS Annual Meeting. The subject, a 26-year-old post-renal transplant immunocompromised individual who developed severe hypoxemic respiratory failure due to COVID-19, was treated with a single dose of agenT-797. Significant clinical improvements included reduced inflammatory cytokines and successful extubation by day 37. The patient was discharged by day 60 and resumed normal activities within six months. These findings align with Phase 1 trial data, supporting the potential of agenT-797 in treating severe respiratory conditions in immune-compromised patients.
MiNK Therapeutics (NASDAQ: INKT) reported its Q1 2024 results, highlighting significant progress in its invariant natural killer T (iNKT) cell therapy programs. Key developments include a $5.8 million private placement financing at a 25% premium, which will expedite the clinical entry of MiNK-215 for solid tumors. Clinical trials for agenT-797 in gastroesophageal cancers are ongoing, with initial results expected later in 2024. Preclinical data showcased MiNK-215's potential in treating MSS colorectal cancer liver metastases. Financially, MiNK ended the quarter with $5.8 million in cash, reduced net losses to $3.8 million (down from $5.7 million in Q1 2023), and decreased operating expenses.
MiNK Therapeutics, Inc. announced a $5.8 million private placement financing to advance the clinical trials of MiNK-215, their leading allogeneic CAR-iNKT cell therapy targeting fibroblast activation protein in solid tumors. The financing includes a 25% premium, selling 4,640,000 shares of common stock at $1.25 per share. The funding will help accelerate the clinical development of MiNK-215, planned to enter the clinic in early 2025. Additionally, Katie Chudnovsky has been appointed as a Board Observer, bringing extensive experience in the medical research field.
MiNK Therapeutics, Inc. (NASDAQ: INKT) will release its first quarter 2024 financial results on May 14, 2024. The company is focused on developing iNKT cell therapies for cancer and immune diseases. An executive conference call and webcast will follow to discuss the results and provide a corporate update.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.